References
[1] Bloch, S.B., Larsen, M. and Munch, I.C. (2012) Incidence of Legal Blindness from Age-Related Macular Degeneration in Denmark: Year 2000 to 2010. American Journal of Ophthalmology, 153, 209-213, e202.
[2] Bressler, N.M., Doan, Q.V., Varma, R., et al. (2011) Estimated Cases of Legal Blindness and Visual Impairment Avoided Using Ranibizumab for Choroidal Neovascularization: Non-Hispanic White Population in the United States with Age-Related Macular Degeneration. Archives of Ophthalmology, 129, 709-717.
http://dx.doi.org/10.1001/archophthalmol.2011.140
[3] Skaat, A., Chetrit, A., Belkin, M., et al. (2012) Time Trends in the Incidence and Causes of Blindness in Israel. American Journal of Ophthalmology, 153, 214-221, e211.
[4] Falkenstein, I.A, Cheng, L. and Freeman, W.R. (2007) Changes of Intraocular Pressure after Intravitreal Injection of Bevacizumab (Avastin). Retina, 27, 1044-1047.
http://dx.doi.org/10.1097/IAE.0b013e3180592ba6
[5] Wu, L. and Evans, T. (2010) [Immediate Changes in Intraocular Pressure after an Intravitreal Injection of 2.5 mg of Bevacizumab]. Archivos de la Sociedad Espanola de Oftalmologia, 85, 364-369.
http://dx.doi.org/10.1016/j.oftal.2010.09.010
[6] Sharei, V., Hohn, F., Kohler, T., et al. (2010) Course of Intraocular Pressure after Intravitreal Injection of 0.05 mL Ranibizumab (Lucentis). European Journal of Ophthalmology, 20, 174-179.
[7] Hariprasad, S.M., Shah, G.K. and Blinder, K.J. (2006) Short-Term Intraocular Pressure Trends Following Intravitreal Pegaptanib (Macugen) Injection. American Journal of Ophthalmology, 141, 200-201.
http://dx.doi.org/10.1016/j.ajo.2005.07.053
[8] Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al. (2006) Ranibizumab for Neovascular Age-Related Macular Degeneration. The New England Journal of Medicine, 355, 1419-1431.
http://dx.doi.org/10.1056/NEJMoa054481
[9] Aiello, L.P., Brucker, A.J., Chang, S., et al. (2004) Evolving Guidelines for Intravitreous Injections. Retina, 24, S3-S19.
http://dx.doi.org/10.1097/00006982-200410001-00002
[10] Frenkel, M.P., Haji, S.A. and Frenkel, R.E. (2010) Effect of Prophylactic Intraocular Pressure-Lowering Medication on Intraocular Pressure Spikes after Intravitreal Injections. Archives of Ophthalmology, 128, 1523-1527.
http://dx.doi.org/10.1001/archophthalmol.2010.297
[11] El Chehab, H., Le Corre, A., Agard, E., et al. (2012) Effect of Topical Pressure-Lowering Medication on Prevention of Intraocular Pressure Spikes after Intravitreal Injection. European Journal of Ophthalmology, 23.
[12] Theoulakis, P.E., Lepidas, J., Petropoulos, I.K., et al. (2010) Effect of Brimonidine/Timolol Fixed Combination on Preventing the Short-Term Intraocular Pressure Increase after Intravitreal Injection of Ranibizumab. Klinische Monatsblatter fur Augenheilkunde, 227, 280-284.
http://dx.doi.org/10.1055/s-0029-1245201
[13] Pruessner, J.C., Kirschbaum, C., Meinlschmid, G., et al. (2003) Two Formulas for Computation of the Area under the Curve Represent Measures of Total Hormone Concentration versus Time-Dependent Change. Psychoneuroendocrinology, 28, 916-931.
http://dx.doi.org/10.1016/S0306-4530(02)00108-7
[14] Robin, A.L., Pollack, I.P., House, B., et al. (1987) Effects of ALO 2145 on Intraocular Pressure Following Argon Laser Trabeculoplasty. Archives of Ophthalmology, 105, 646-650.
http://dx.doi.org/10.1001/archopht.1987.01060050064039
[15] Barnes, S.D., Campagna, J.A., Dirks, M.S., et al. (1999) Control of Intraocular Pressure Elevations after Argon Laser Trabeculoplasty: Comparison of Brimonidine 0.2% to Apraclonidine 1.0%. Ophthalmology, 106, 2033-2037.
http://dx.doi.org/10.1016/S0161-6420(99)90420-7
[16] Ladas, I.D., Baltatzis, S., Panagiotidis, D., et al. (1997) Topical 2.0% Dorzolamide vs oral Acetazolamide for Prevention of Intraocular Pressure Rise after Neodymium:YAG Laser Posterior Capsulotomy. Archives of Ophthalmology, 115, 1241-1244.
http://dx.doi.org/10.1001/archopht.1997.01100160411003
[17] Wilensky, J.T., Gieser, D.K., Dietsche, M.L., et al. (1993) Individual Variability in the Diurnal Intraocular Pressure Curve. Ophthalmology, 100, 940-944.
http://dx.doi.org/10.1016/S0161-6420(93)31551-4
[18] Kim, J.E., Mantravadi, A.V., Hur, E.Y., et al. (2008) Short-Term Intraocular Pressure Changes Immediately after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents. American Journal of Ophthalmology, 146, 930-934, e931.
[19] Hollands, H., Wong, J., Bruen, R., et al. (2007) Short-Term Intraocular Pressure Changes after Intravitreal Injection of Bevacizumab. Canadian Journal of Ophthalmology, 42, 807-811.
http://dx.doi.org/10.3129/i07-172
[20] Pallikaris, I.G., Kymionis, G.D., Ginis, H.S., et al. (2005) Ocular Rigidity in Living Human Eyes. Investigative Ophthalmology & Visual Science, 46, 409-414.
http://dx.doi.org/10.1167/iovs.04-0162
[21] Detry-Morel, M. (2008) Currents on Target Intraocular Pressure and Intraocular Pressure Fluctuations in Glaucoma Management. Bulletin de la Societe belge d’ophtalmologie, 35-43.
[22] Realini, T., Barber, L. and Burton, D. (2002) Frequency of Asymmetric Intraocular Pressure Fluctuations among Patients with and without Glaucoma. Ophthalmology, 109, 1367-1371.
http://dx.doi.org/10.1016/S0161-6420(02)01073-4
[23] Zeimer, R.C., Wilensky, J.T., Gieser, D.K., et al. (1991) Association between Intraocular Pressure Peaks and Progression of Visual Field Loss. Ophthalmology, 98, 64-69.
http://dx.doi.org/10.1016/S0161-6420(91)32340-6